secwatch.observer — SEC 8-K summary
======================================

Issuer:     PERRIGO Co plc (PRGO)
CIK:        0001585364
Form:       8-K
Filed at:   2024-07-10T23:59:59+00:00
Accession:  0001193125-24-177015
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perrigo completes divestiture of HRA Pharma Rare Diseases to Esteve for up to €275M
--------------------------------------------------------------------------------

- Total consideration up to €275M: €190M upfront cash plus up to €85M in earnout based on sales milestones.
- Proceeds to be redeployed for debt repayment; impact included in previously issued 2024 outlook.
- Rare Diseases business had FY2023 net sales of ~€50M and adjusted EBITDA of ~€20M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585364/000119312524177015/0001193125-24-177015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585364/000119312524177015/d846136d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-177015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer